KR102209353B1 - 파킨슨 병 치료 방법 - Google Patents

파킨슨 병 치료 방법 Download PDF

Info

Publication number
KR102209353B1
KR102209353B1 KR1020157028984A KR20157028984A KR102209353B1 KR 102209353 B1 KR102209353 B1 KR 102209353B1 KR 1020157028984 A KR1020157028984 A KR 1020157028984A KR 20157028984 A KR20157028984 A KR 20157028984A KR 102209353 B1 KR102209353 B1 KR 102209353B1
Authority
KR
South Korea
Prior art keywords
levodopa
carbidopa
administered
parkinson
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157028984A
Other languages
English (en)
Korean (ko)
Other versions
KR20150131230A (ko
Inventor
오론 야코비-제에비
Original Assignee
뉴로덤 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50513395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102209353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴로덤 엘티디 filed Critical 뉴로덤 엘티디
Publication of KR20150131230A publication Critical patent/KR20150131230A/ko
Application granted granted Critical
Publication of KR102209353B1 publication Critical patent/KR102209353B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020157028984A 2013-03-13 2014-03-13 파킨슨 병 치료 방법 Active KR102209353B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779357P 2013-03-13 2013-03-13
US61/779,357 2013-03-13
PCT/IL2014/050261 WO2014141261A1 (en) 2013-03-13 2014-03-13 Method for treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
KR20150131230A KR20150131230A (ko) 2015-11-24
KR102209353B1 true KR102209353B1 (ko) 2021-01-29

Family

ID=50513395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028984A Active KR102209353B1 (ko) 2013-03-13 2014-03-13 파킨슨 병 치료 방법

Country Status (21)

Country Link
US (4) US20160022573A1 (enExample)
EP (2) EP3892266A1 (enExample)
JP (2) JP6472391B2 (enExample)
KR (1) KR102209353B1 (enExample)
CN (2) CN105209029A (enExample)
AU (1) AU2014229127B2 (enExample)
BR (1) BR112015022390A8 (enExample)
CA (1) CA2904838C (enExample)
CL (1) CL2015002641A1 (enExample)
DK (1) DK2968218T3 (enExample)
ES (1) ES2889626T3 (enExample)
HR (1) HRP20211442T1 (enExample)
HU (1) HUE056006T2 (enExample)
IL (1) IL266648B (enExample)
MX (1) MX365206B (enExample)
PL (1) PL2968218T3 (enExample)
PT (1) PT2968218T (enExample)
RU (2) RU2018144700A (enExample)
SG (2) SG11201507538UA (enExample)
WO (1) WO2014141261A1 (enExample)
ZA (1) ZA201507621B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627655T3 (es) 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
PL2640370T3 (pl) 2010-11-15 2018-09-28 Neuroderm Ltd Kompozycje do dostarczania przezskórnego substancji czynnych
PT3116475T (pt) * 2014-03-13 2020-12-15 Neuroderm Ltd Composições de inibidores de dopa-descarboxilase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
JP6567049B2 (ja) 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
SMT202100247T1 (it) * 2017-06-05 2021-05-07 Dizlin Pharmaceuticals Ab Soluzione per infusione di levodopa
WO2019097120A1 (en) * 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
WO2019147934A1 (en) * 2018-01-29 2019-08-01 Sackner Bernstein Jonathan Methods for dopamine modulation in human neurologic diseases
JP2021517128A (ja) * 2018-03-29 2021-07-15 アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー レボドパ分割用量組成物および使用
CA3117983A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2023282900A1 (en) * 2021-07-08 2023-01-12 Morehouse School Of Medicine Method and system of diagnosing and treating neurodegenerative disease and seizures
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298428A1 (en) 2009-05-19 2010-11-25 Oron Yacoby-Zeevi Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
KR101617990B1 (ko) * 2005-06-08 2016-05-03 오리온 코포레이션 경구 용량 형태
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298428A1 (en) 2009-05-19 2010-11-25 Oron Yacoby-Zeevi Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Neurology, 19(6), 820-826, 2012.

Also Published As

Publication number Publication date
RU2677278C2 (ru) 2019-01-16
HRP20211442T1 (hr) 2022-02-04
CA2904838C (en) 2021-03-16
AU2014229127A1 (en) 2015-11-05
RU2015143112A (ru) 2017-04-20
JP6472391B2 (ja) 2019-02-20
US20250177292A1 (en) 2025-06-05
WO2014141261A1 (en) 2014-09-18
HUE056006T2 (hu) 2022-01-28
CA2904838A1 (en) 2014-09-18
MX365206B (es) 2019-05-27
EP2968218B1 (en) 2021-07-07
SG10201911731YA (en) 2020-02-27
BR112015022390A8 (pt) 2019-11-26
US20210093560A1 (en) 2021-04-01
CL2015002641A1 (es) 2016-03-18
JP6625773B2 (ja) 2019-12-25
KR20150131230A (ko) 2015-11-24
CN105209029A (zh) 2015-12-30
IL266648A (en) 2019-07-31
IL266648B (en) 2020-08-31
MX2015012561A (es) 2016-06-28
JP2019070041A (ja) 2019-05-09
CN110935026A (zh) 2020-03-31
ZA201507621B (en) 2019-04-24
ES2889626T3 (es) 2022-01-12
US20230047847A1 (en) 2023-02-16
PL2968218T3 (pl) 2022-01-10
EP3892266A1 (en) 2021-10-13
DK2968218T3 (da) 2021-09-20
SG11201507538UA (en) 2015-10-29
EP2968218A1 (en) 2016-01-20
JP2016512230A (ja) 2016-04-25
BR112015022390A2 (pt) 2017-07-18
PT2968218T (pt) 2021-09-24
AU2014229127B2 (en) 2018-04-05
US20160022573A1 (en) 2016-01-28
RU2018144700A (ru) 2019-02-18

Similar Documents

Publication Publication Date Title
KR102209353B1 (ko) 파킨슨 병 치료 방법
US20250114315A1 (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
HK40012262A (zh) L-多巴、多巴脱羧酶抑制剂、儿茶酚-0-甲基转移酶抑制剂及其组合物的连续施用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190307

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201102

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240109

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250108

Start annual number: 5

End annual number: 5